"Neprilysin" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Enzyme that is a major constituent of kidney brush-border membranes and is also present to a lesser degree in the brain and other tissues. It preferentially catalyzes cleavage at the amino group of hydrophobic residues of the B-chain of insulin as well as opioid peptides and other biologically active peptides. The enzyme is inhibited primarily by EDTA, phosphoramidon, and thiorphan and is reactivated by zinc. Neprilysin is identical to common acute lymphoblastic leukemia antigen (CALLA Antigen), an important marker in the diagnosis of human acute lymphocytic leukemia. There is no relationship with CALLA PLANT.
Descriptor ID |
D015260
|
MeSH Number(s) |
D08.811.277.656.300.480.600 D08.811.277.656.675.374.600 D23.050.285.550 D23.101.140.500
|
Concept/Terms |
Neprilysin- Neprilysin
- CALLA Antigen
- Enkephalinase
- Enkephalinase-24.11
- Enkephalinase 24.11
- Kidney-Brush-Border Neutral Proteinase
- Kidney Brush Border Neutral Proteinase
- Neutral Proteinase, Kidney-Brush-Border
- Membrane Metallo-Endopeptidase
- Membrane Metallo Endopeptidase
- Metallo-Endopeptidase, Membrane
- Neutral Endopeptidase
- Endopeptidase, Neutral
- Neutral Endopeptidase 24.11
- Endopeptidase 24.11, Neutral
- Thermolysin-Like Metalloendopeptidase
- Metalloendopeptidase, Thermolysin-Like
- Thermolysin Like Metalloendopeptidase
- YGG-Forming Enzyme
- Enzyme, YGG-Forming
- YGG Forming Enzyme
- Common Acute Lymphoblastic Leukemia Antigens
- Antigens, Leukemia, Common Acute Lymphoblastic
- Atriopeptidase
- CD10 Antigen
- Antigen, CD10
- Antigens, CD10
- CD10 Antigens
- Endopeptidase-24.11
- Endopeptidase 24.11
- Enkephalin Dipeptidyl Carboxypeptidase
- Carboxypeptidase, Enkephalin Dipeptidyl
- Dipeptidyl Carboxypeptidase, Enkephalin
|
Below are MeSH descriptors whose meaning is more general than "Neprilysin".
Below are MeSH descriptors whose meaning is more specific than "Neprilysin".
This graph shows the total number of publications written about "Neprilysin" by people in this website by year, and whether "Neprilysin" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
Year | Major Topic | Minor Topic | Total |
---|
2018 | 3 | 0 | 3 |
2019 | 1 | 0 | 1 |
2020 | 3 | 0 | 3 |
2021 | 0 | 2 | 2 |
2022 | 0 | 1 | 1 |
To return to the timeline,
click here.
Below are the most recent publications written about "Neprilysin" by people in Profiles.
-
Risk of Acute Kidney Injury Among Older Adults With Heart Failure and With Reduced Ejection Fraction Treated With Angiotensin-Neprilysin Inhibitor vs Renin-Angiotensin System Inhibitor in Routine Clinical Care. J Card Fail. 2023 Feb; 29(2):138-146.
-
Potential Implications of Expanded US Food and Drug Administration Labeling for Sacubitril/Valsartan in the US. JAMA Cardiol. 2021 12 01; 6(12):1415-1423.
-
Incidence and Outcomes of Pneumonia in Patients With Heart Failure. J Am Coll Cardiol. 2021 04 27; 77(16):1961-1973.
-
Angiotensin-Neprilysin Inhibition in Black Americans: Data From the PIONEER-HF Trial. JACC Heart Fail. 2020 10; 8(10):859-866.
-
Angiotensin Receptor-Neprilysin Inhibition Based on History of Heart Failure and Use of Renin-Angiotensin System Antagonists. J Am Coll Cardiol. 2020 09 01; 76(9):1034-1048.
-
Initiation of Angiotensin-Neprilysin Inhibition After Acute Decompensated Heart Failure: Secondary Analysis of the Open-label Extension of the PIONEER-HF Trial. JAMA Cardiol. 2020 02 01; 5(2):202-207.
-
Angiotensin-neprilysin inhibition in de novo heart failure - starting off strong. Eur J Heart Fail. 2020 02; 22(2):313-314.
-
Angiotensin-Neprilysin Inhibition in Acute Decompensated Heart Failure. N Engl J Med. 2019 02 07; 380(6):539-548.
-
The role of angiotensin receptor-neprilysin inhibitors in cardiovascular disease-existing evidence, knowledge gaps, and future directions. Eur J Heart Fail. 2018 06; 20(6):963-972.
-
Angiotensin receptor-neprilysin inhibitor therapy in heart failure: An end that justifies the means. Am Heart J. 2018 05; 199:176-177.